文献速递前列腺癌

挪威男性中的机会性前列腺特异性抗原检测:一项公共卫生挑战

Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
PubMed 文献 · BJU Int · 2023-11-02

PSA值在3至7 ng/mL区间内良恶性广泛重叠,局限性前列腺癌诊断从45岁至75岁增加10倍,提示机会性PSA检测随年龄增长而增加且特异性下降。

要点

  • PSA值在3至7 ng/mL区间内良恶性广泛重叠,难以区分良性前列腺增生与前列腺癌。
  • 局限性前列腺癌诊断从45岁至75岁增加10倍。
  • 50-54岁男性中21%(95%CI 19-23%)检出中或高级别癌,70-74岁为42%(95%CI 41-43%)。

核心结论

  • 机会性PSA检测随年龄增长而增加,常产生无法区分良性前列腺增生与前列腺癌的数值。
  • 需要采用包括额外影像或血清检测的临床流程以避免阴性活检和惰性疾病的过度诊断。
  • PSA检测特异性随年龄增长而下降,在≥70岁老年男性中构成重大公共卫生挑战。

研究设计与样本

  • 期间共43 486名男性被诊断为局限性前列腺癌,大多数PSA检测反映机会性检测。
  • 为45-75岁患有和不患有前列腺癌的男性构建了年龄特异性PSA值分布。

主要发现

  • 患有和不患有前列腺癌的男性PSA值分布随年龄增长而增宽,且在3至7 ng/mL区间内广泛重叠。
  • 局限性前列腺癌诊断从45岁至75岁增加10倍。
  • PSA检测在50-54岁男性中检出21%(95%CI 19-23%)的中或高级别癌,在70-74岁男性中检出42%(95%CI 41-43%)。
  • 在50-54岁确诊的癌症中,GG1、GG2、GG3和≥GG4分别占49%、31%、10%和10%;在70-74岁确诊的癌症中分别占26%、26%、18%和30%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide opportunistic PSA testing. PATIENTS AND METHODS: Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age-specific PSA value distributions were constructed for men aged 45-75 years with and without prostate cancer. RESULTS: The distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10-fold from the age of 45 to 75 years. PSA testing identified intermediate- or high-grade cancers in 21% (95% confidence interval [CI] 19-23%) of men aged 50-54 years and 42% (95% CI 41-43%) of men aged 70-74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50-54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70-74 years. CONCLUSION: Opportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Albertsen PC, Bjerner LJ, Pasovic L, et al. Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge. BJU Int. 2023. PMID: 37869764. doi:10.1111/bju.16211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。